ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Lower drug uptake or increased drug extrusion can create an environment conducive to the development of additional resistance mechanisms, such as BCR::ABL1 mutations, emphasizing the importance of personalized treatment strategies targeting drug transporters to optimize therapeutic outcomes in CML.